388 related articles for article (PubMed ID: 25687212)
21. Structure, mechanism, and inhibition of histone deacetylases and related metalloenzymes.
Lombardi PM; Cole KE; Dowling DP; Christianson DW
Curr Opin Struct Biol; 2011 Dec; 21(6):735-43. PubMed ID: 21872466
[TBL] [Abstract][Full Text] [Related]
22. Innovative Strategies for Selective Inhibition of Histone Deacetylases.
Maolanon AR; Madsen AS; Olsen CA
Cell Chem Biol; 2016 Jul; 23(7):759-768. PubMed ID: 27447046
[TBL] [Abstract][Full Text] [Related]
23. Design and synthesis of aryl ether and sulfone hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
Pabba C; Gregg BT; Kitchen DB; Chen ZJ; Judkins A
Bioorg Med Chem Lett; 2011 Jan; 21(1):324-8. PubMed ID: 21109435
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.
Bürli RW; Luckhurst CA; Aziz O; Matthews KL; Yates D; Lyons KA; Beconi M; McAllister G; Breccia P; Stott AJ; Penrose SD; Wall M; Lamers M; Leonard P; Müller I; Richardson CM; Jarvis R; Stones L; Hughes S; Wishart G; Haughan AF; O'Connell C; Mead T; McNeil H; Vann J; Mangette J; Maillard M; Beaumont V; Munoz-Sanjuan I; Dominguez C
J Med Chem; 2013 Dec; 56(24):9934-54. PubMed ID: 24261862
[TBL] [Abstract][Full Text] [Related]
25. Structural origin of selectivity in class II-selective histone deacetylase inhibitors.
Estiu G; Greenberg E; Harrison CB; Kwiatkowski NP; Mazitschek R; Bradner JE; Wiest O
J Med Chem; 2008 May; 51(10):2898-906. PubMed ID: 18412327
[TBL] [Abstract][Full Text] [Related]
26. Design of Potent Panobinostat Histone Deacetylase Inhibitor Derivatives: Molecular Considerations for Enhanced Isozyme Selectivity between HDAC2 and HDAC8.
Stoddard SV; May XA; Rivas F; Dodson K; Vijayan S; Adhika S; Parker K; Watkins DL
Mol Inform; 2019 Mar; 38(3):e1800080. PubMed ID: 30369061
[TBL] [Abstract][Full Text] [Related]
27. Molecular modeling study on tunnel behavior in different histone deacetylase isoforms.
Thangapandian S; John S; Lee Y; Arulalapperumal V; Lee KW
PLoS One; 2012; 7(11):e49327. PubMed ID: 23209570
[TBL] [Abstract][Full Text] [Related]
28. Natural products as zinc-dependent histone deacetylase inhibitors.
Tan S; Liu ZP
ChemMedChem; 2015 Mar; 10(3):441-50. PubMed ID: 25581683
[TBL] [Abstract][Full Text] [Related]
29. Design, synthesis, biological evaluation, and structural characterization of potent histone deacetylase inhibitors based on cyclic alpha/beta-tetrapeptide architectures.
Montero A; Beierle JM; Olsen CA; Ghadiri MR
J Am Chem Soc; 2009 Mar; 131(8):3033-41. PubMed ID: 19239270
[TBL] [Abstract][Full Text] [Related]
30. Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitors.
Whitehead L; Dobler MR; Radetich B; Zhu Y; Atadja PW; Claiborne T; Grob JE; McRiner A; Pancost MR; Patnaik A; Shao W; Shultz M; Tichkule R; Tommasi RA; Vash B; Wang P; Stams T
Bioorg Med Chem; 2011 Aug; 19(15):4626-34. PubMed ID: 21723733
[TBL] [Abstract][Full Text] [Related]
31. Ligand and structure based pharmacophore modeling to facilitate novel histone deacetylase 8 inhibitor design.
Thangapandian S; John S; Sakkiah S; Lee KW
Eur J Med Chem; 2010 Oct; 45(10):4409-17. PubMed ID: 20656379
[TBL] [Abstract][Full Text] [Related]
32. A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity.
Zhang XH; Qin-Ma ; Wu HP; Khamis MY; Li YH; Ma LY; Liu HM
J Med Chem; 2021 Feb; 64(3):1362-1391. PubMed ID: 33523672
[TBL] [Abstract][Full Text] [Related]
33. Environment-sensitive fluorescent inhibitors of histone deacetylase.
Zhou X; Dong G; Song T; Wang G; Li Z; Qin X; Du L; Li M
Bioorg Med Chem Lett; 2020 Jun; 30(11):127128. PubMed ID: 32247729
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis and preliminary activity assay of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as novel Histone deacetylases (HDACs) inhibitors.
Zhang Y; Feng J; Liu C; Zhang L; Jiao J; Fang H; Su L; Zhang X; Zhang J; Li M; Wang B; Xu W
Bioorg Med Chem; 2010 Mar; 18(5):1761-72. PubMed ID: 20171895
[TBL] [Abstract][Full Text] [Related]
35. Energy-optimised pharmacophore approach to identify potential hotspots during inhibition of Class II HDAC isoforms.
Ganai SA; Shanmugam K; Mahadevan V
J Biomol Struct Dyn; 2015; 33(2):374-87. PubMed ID: 24460542
[TBL] [Abstract][Full Text] [Related]
36. Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy.
Luan Y; Li J; Bernatchez JA; Li R
J Med Chem; 2019 Apr; 62(7):3171-3183. PubMed ID: 30418766
[TBL] [Abstract][Full Text] [Related]
37. Oxime amides as a novel zinc binding group in histone deacetylase inhibitors: synthesis, biological activity, and computational evaluation.
Botta CB; Cabri W; Cini E; De Cesare L; Fattorusso C; Giannini G; Persico M; Petrella A; Rondinelli F; Rodriquez M; Russo A; Taddei M
J Med Chem; 2011 Apr; 54(7):2165-82. PubMed ID: 21417297
[TBL] [Abstract][Full Text] [Related]
38. Inside HDACs with more selective HDAC inhibitors.
Roche J; Bertrand P
Eur J Med Chem; 2016 Oct; 121():451-483. PubMed ID: 27318122
[TBL] [Abstract][Full Text] [Related]
39. Strategies To Design Selective Histone Deacetylase Inhibitors.
Melesina J; Simoben CV; Praetorius L; Bülbül EF; Robaa D; Sippl W
ChemMedChem; 2021 May; 16(9):1336-1359. PubMed ID: 33428327
[TBL] [Abstract][Full Text] [Related]
40. Isoform-specific histone deacetylase inhibitors: the next step?
Balasubramanian S; Verner E; Buggy JJ
Cancer Lett; 2009 Aug; 280(2):211-21. PubMed ID: 19289255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]